Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism

ACS Medicinal Chemistry Letters

Volumn 7, Issue 11, 2016, Pages 977-982

  Nathan Tumey, L ^a   Leverett, Carolyn A ^a   Vetelino, Beth ^a   Li, Fengping ^a   Rago, Brian ^a   Han, Xiaogang ^a   Loganzo, Frank ^a   Musto, Sylvia ^a   Bai, Guoyun ^a   Sukuru, Sai Chetan K ^a   Graziani, Edmund I ^a   Puthenveetil, Sujiet ^a   Casavant, Jeffrey ^a   Ratnayake, Anokha ^a   Marquette, Kimberly ^a   Hudson, Sarah ^a,b   Doppalapudi, Venkata Ramana ^a   Stock, Joseph ^a,c   Tchistiakova, Lioudmila ^a   Bessire, Andrew J ^a   Clark, Tracey ^a   Lucas, Judy ^a   Hosselet, Christine ^a   O'Donnell, Christopher J ^a   Subramanyam, Chakrapani ^a   more..

^a PFIZER INC   (United States)

^b SBP Medical Discovery Institute   (United States)

^c Solstice Biologics   (United States)

Author keywords

Antibody drug conjugate (ADC); hydrophobic interaction chromatograph (HIC); plasma stability; tubulysin

Indexed keywords

ANTIBODY CONJUGATE; CARBAMIC ACID; FUNCTIONAL GROUP; TUBULIN; TUBULYSIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84994888072     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00195     Document Type: Article

References (25)

1. Thomas, A.; Teicher, B. A.; Hassan, R. Antibody-drug conjugates for cancer therapy Lancet Oncol. 2016, 17, e254 10.1016/S1470-2045(16)30030-4
2. O'Hear, C.; Rubnitz, J. E. Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback? Expert Rev. Hematol. 2014, 7, 427-429 10.1586/17474086.2014.924849
3. Akkapeddi, P.; Azizi, S.; Freedy, A. M.; Cal, P. M. S. D.; Gois, P. M. P.; Bernardes, G. J. L. Construction of homogeneous antibody-drug conjugates using site-selective protein chemistry Chem. Sci. 2016, 7, 2954 10.1039/C6SC00170J
4. Bessire, A. J.; Ballard, T. E.; Charati, M.; Cohen, J. D.; Green, M. E.; Lam, M.; Loganzo, F.; Nolting, B.; Pierce, B.; Puthenveetil, S.; Roberts, L.; Schildknegt, K.; Subramanyam, C. Determination of antibody-Drug-Conjugate Released Payload Species Using Directed In Vitro Assays and Mass Spectrometric Interrogation Bioconjugate Chem. 2016, 10.1021/acs.bioconjchem.6b00192
5. Klute, K.; Nackos, E.; Tasaki, S.; Nguyen, D. P.; Bander, N. H.; Tagawa, S. T. Microtubule inhibitor-based antibody-drug conjugates for cancer therapy OncoTargets Ther. 2014, 7, 2227 10.2147/OTT.S46887
6. Murray, B. C.; Peterson, M. T.; Fecik, R. A. Chemistry and biology of tubulysins: antimitotic tetrapeptides with activity against drug resistant cancers Nat. Prod. Rep. 2015, 32, 654-662 10.1039/C4NP00036F
7. Kaur, G.; Hollingshead, M.; Holbeck, S.; Schauer-Vukasinovic, V.; Camalier, R. F.; Domling, A.; Agarwal, S. Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product Biochem. J. 2006, 396, 235-242 10.1042/BJ20051735
8. Reddy, J. A.; Dorton, R.; Dawson, A.; Vetzel, M.; Parker, N.; Nicoson, J. S.; Westrick, E.; Klein, P. J.; Wang, Y.; Vlahov, I. R.; Leamon, C. P. In vivo structural activity and optimization studies of folate-tubulysin conjugates Mol. Pharmaceutics 2009, 6, 1518-1525 10.1021/mp900086w
9. Kularatne, S. A.; Venkatesh, C.; Santhapuram, H. K.; Wang, K.; Vaitilingam, B.; Henne, W. A.; Low, P. S. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs J. Med. Chem. 2010, 53, 7767-7777 10.1021/jm100729b
10. Li, J. Y.; Perry, S. R.; Muniz-Medina, V.; Wang, X.; Wetzel, L. K.; Rebelatto, M. C.; Hinrichs, M. J.; Bezabeh, B. Z.; Fleming, R. L.; Dimasi, N.; Feng, H.; Toader, D.; Yuan, A. Q.; Xu, L.; Lin, J.; Gao, C.; Wu, H.; Dixit, R.; Osbourn, J. K.; Coats, S. R. A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy Cancer Cell 2016, 29, 117-129 10.1016/j.ccell.2015.12.008
11. Tumey, L. N.; Rago, B.; Han, X. In vivo biotransformations of antibody-drug conjugates Bioanalysis 2015, 7, 1649-1664 10.4155/bio.15.84
12. Dokter, W.; Ubink, R.; van der Lee, M.; van der Vleuten, M.; van Achterberg, T.; Jacobs, D.; Loosveld, E.; van den Dobbelsteen, D.; Egging, D.; Mattaar, E.; Groothuis, P.; Beusker, P.; Coumans, R.; Elgersma, R.; Menge, W.; Joosten, J.; Spijker, H.; Huijbregts, T.; de Groot, V.; Eppink, M.; de Roo, G.; Verheijden, G.; Timmers, M. Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform Mol. Cancer Ther. 2014, 13, 2618-2629 10.1158/1535-7163.MCT-14-0040-T
13. Leverett, C. A. Submitted, 2016.
14. Stefano, J. E.; Busch, M.; Hou, L.; Park, A.; Gianolio, D. A. Micro- and mid-scale maleimide-based conjugation of cytotoxic drugs to antibody hinge region thiols for tumor targeting Methods Mol. Biol. (N. Y., NY, U. S.) 2013, 1045, 145-171 10.1007/978-1-62703-541-5-9
15. Patterson, A. W.; Peltier, H. M.; Sasse, F.; Ellman, J. A. Design, synthesis, and biological properties of highly potent tubulysin D analogues Chem.-Eur. J. 2007, 13, 9534-9541 10.1002/chem.200701057
16. Tumey, L. N.; Charati, M.; He, T.; Sousa, E.; Ma, D.; Han, X.; Clark, T.; Casavant, J.; Loganzo, F.; Barletta, F.; Lucas, J.; Graziani, E. I. Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy Bioconjugate Chem. 2014, 25 (10) 1871 10.1021/bc500357n
17. Wang, Y.; Benz, F. W.; Wu, Y.; Wang, Q.; Chen, Y.; Chen, X.; Li, H.; Zhang, Y.; Zhang, R.; Yang, J. Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules Mol. Pharmacol. 2016, 89, 233-242 10.1124/mol.115.100149
18. Wei, C.; Zhang, G.; Clark, T.; Barletta, F.; Tumey, L. N.; Rago, B.; Hansel, S.; Han, X. Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma Anal. Chem. 2016, 88 (9) 4979 10.1021/acs.analchem.6b00976
19. Strop, P.; Liu, S.-H.; Dorywalska, M.; Delaria, K.; Dushin, R. G.; Tran, T.-T.; Ho, W.-H.; Farias, S.; Casas, M. G.; Abdiche, Y.; Zhou, D.; Chandrasekaran, R.; Samain, C.; Loo, C.; Rossi, A.; Rickert, M.; Krimm, S.; Wong, T.; Chin, S. M.; Yu, J.; Dilley, J.; Chaparro-Riggers, J.; Filzen, G. F.; O'Donnell, C. J.; Wang, F.; Myers, J. S.; Pons, J.; Shelton, D. L.; Rajpal, A. Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates Chem. Biol. 2013, 20, 161-167 10.1016/j.chembiol.2013.01.010
20. Dorywalska, M.; Strop, P.; Melton-Witt, J. A.; Hasa-Moreno, A.; Farias, S. E.; Galindo Casas, M.; Delaria, K.; Lui, V.; Poulsen, K.; Loo, C.; Krimm, S.; Bolton, G.; Moine, L.; Dushin, R.; Tran, T. T.; Liu, S. H.; Rickert, M.; Foletti, D.; Shelton, D. L.; Pons, J.; Rajpal, A. Effect of attachment site on stability of cleavable antibody drug conjugates Bioconjugate Chem. 2015, 26, 650-659 10.1021/bc5005747
21. Lyon, R. P.; Bovee, T. D.; Doronina, S. O.; Burke, P. J.; Hunter, J. H.; Neff-LaFord, H. D.; Jonas, M.; Anderson, M. E.; Setter, J. R.; Senter, P. D. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index Nat. Biotechnol. 2015, 33, 733-735 10.1038/nbt.3212
22. Ouyang, J. Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography Methods Mol. Biol. (N. Y., NY, U. S.) 2013, 1045, 275-283 10.1007/978-1-62703-541-5-17
23. Junutula, J. R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D. D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S. P.; Dennis, M. S.; Lu, Y.; Meng, Y. G.; Ng, C.; Yang, J.; Lee, C. C.; Duenas, E.; Gorrell, J.; Katta, V.; Kim, A.; McDorman, K.; Flagella, K.; Venook, R.; Ross, S.; Spencer, S. D.; Wong, W. L.; Lowman, H. B.; Vandlen, R.; Sliwkowski, M. X.; Scheller, R. H.; Polakis, P.; Mallet, W. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 2008, 26 (8) 925 10.1038/nbt.1480
24. Agarwal, P.; Bertozzi, C. R. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development Bioconjugate Chem. 2015, 26, 176 10.1021/bc5004982
25. Tian, F.; Lu, Y.; Manibusan, A.; Sellers, A.; Tran, H.; Sun, Y.; Phuong, T.; Barnett, R.; Hehli, B.; Song, F.; De Guzman, M. J.; Ensari, S.; Pinkstaff, J. K.; Sullivan, L. M.; Biroc, S. L.; Cho, H.; Schultz, P. G.; Di Joseph, J.; Dougher, M.; Ma, D.; Dushin, R.; Leal, M.; Tchistiakova, L.; Feyfant, E.; Gerber, H.-P.; Sapra, P. A general approach to site-specific antibody drug conjugates Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 1766-1771 10.1073/pnas.1321237111